Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: Project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 21, Issue 2, 2014, Pages 148-158

  Motoi, Fuyuhiko ^a   Unno, Michiaki ^a   Takahashi, Hidenori ^b   Okada, Takaho ^a   Wada, Keita ^c   Sho, Masayuki ^d   Nagano, Hiroaki ^e   Matsumoto, Ippei ^f   Satoi, Sohei ^g   Murakami, Yoshiaki ^h   Kishiwada, Masashi ⁱ   Honda, Goro ^j   Kinoshita, Hisafumi ^k   Baba, Hideo ^l   Hishinuma, Shoichi ^m   Kitago, Minoru ⁿ   Tajima, Hidehiro ^o   Shinchi, Hiroyuki ^p   Takamori, Hiroshi ^q   Kosuge, Tomoo ^r   Yamaue, Hiroki ^s   Takada, Tadahiro ^t   more..

^a TOHOKU UNIVERSITY   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c TEIKYO UNIVERSITY   (Japan)

^d NARA MEDICAL UNIVERSITY   (Japan)

^e OSAKA UNIVERSITY   (Japan)

^f KOBE UNIVERSITY   (Japan)

^g KANSAI MEDICAL UNIVERSITY   (Japan)

^h HIROSHIMA UNIVERSITY   (Japan)

ⁱ MIE UNIVERSITY   (Japan)

^j TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^k KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l KUMAMOTO UNIVERSITY   (Japan)

^m TOCHIGI CANCER CENTER   (Japan)

ⁿ KEIO UNIVERSITY   (Japan)

^o KANAZAWA UNIVERSITY   (Japan)

^p KAGOSHIMA UNIVERSITY   (Japan)

^q SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

^r NATIONAL CANCER CENTER HOSPITAL   (Japan)

^s WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^t Japanese Society of Pancreatic Surgery   (Japan)

more..

Author keywords

Neoadjuvant; Pancreatic cancer; Perioperative outcome; Resectability; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ALLERGY; ANEMIA; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CHOLANGITIS; CHOLECYSTITIS; CONTROLLED STUDY; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; LENGTH OF STAY; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; OPERATION DURATION; OPERATIVE BLOOD LOSS; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PANCREAS FISTULA; PNEUMONIA; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; RADIATION INJURY; REOPERATION; SURGICAL MORTALITY; THROMBOCYTOPENIA; VERY ELDERLY; ADJUVANT THERAPY; CANCER STAGING; GENERAL SURGERY; JAPAN; MEDICAL SOCIETY; MORTALITY; PANCREATIC NEOPLASMS; PATHOLOGY; PREOPERATIVE CARE; QUESTIONNAIRE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BLOOD LOSS, SURGICAL; FEMALE; GENERAL SURGERY; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OPERATIVE TIME; PANCREATIC NEOPLASMS; PREOPERATIVE CARE; QUESTIONNAIRES; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 84897082482     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1002/jhbp.15     Document Type: Article

References (28)

1. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al.; European Study Group for Pancreatic Cancer. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomised controlled trial. Lancet. 2001;358:1576-85.
2. Stocken DD, Büchler MW, Dervenis C, Bassi C, Jeekel H, Klinkenbijl JH, et al.; Pancreatic Cancer Meta-analysis Group. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer. 2005;92:1372-81.
3. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA. 2007;297:267-77.
4. Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101:908-15.
5. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al.; European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA. 2010;304:1073-81.
6. Kaufmann M, Morrow M, von Minckwitz G, Harris JR, Biedenkopf Expert Panel Members. Locoregional treatment of primary breast cancer: Consensus recommendations from an International Expert Panel. Cancer. 2010;116:1184-91.
7. Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68-74.
8. Palmer DH, Stocken DD, Hewitt H, Markham CE, Hassan AB, Johnson PJ, et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: Gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol. 2007;14:2088-96.
9. Heinrich S, Pestalozzi BC, Schäfer M, Weber A, Bauerfeind P, Knuth A, et al. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26:2526-31.
10. Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3487-95.
11. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496-502.
12. Reni M. Neoadjuvant treatment for resectable pancreatic cancer: Time for phase III testing?World J Gastroenterol. 2010;16:4883-7.
13. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Pancreatic adenocarcinoma, version 2.2010. http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp
14. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, Version 3.0. http://ctep.cancer.gov
15. Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, et al.; International Study Group on Pancreatic Fistula Definition. Postoperative pancreatic fistula: An international study group (ISGPF) definition. Surgery. 2005;138:8-13.
16. Wente MN, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR, et al. Delayed gastric emptying (DGE) after pancreatic surgery: A suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007;142:761-8.
17. Andriulli A, Festa V, Botteri E, Valvano MR, Koch M, Bassi C, et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: A meta-analysis of prospective studies. Ann Surg Oncol. 2012;19:1644-62.
18. Heinrich S, Pestalozzi B, Lesurtel M, Berrevoet F, Laurent S, Delpero JR, et al. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: A randomized multicenter phase III study (NEOPAC study). BMC Cancer. 2011;11:346.
19. Le Scodan R, Mornex F, Girard N, Mercier C, Valette PJ, Ychou M, et al. Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: Feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. Ann Oncol. 2009;20:1387-96.
20. Stessin AM, Meyer JE, Sherr DL. Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: An analysis of data from the surveillance, epidemiology, and end results (SEER) registry. Int J Radiat Oncol Biol Phys. 2008;72:1128-33.
21. Sata N, Kurashina K, Nagai H, Nagakawa T, Ishikawa O, Ohta T, et al. The effect of adjuvant and neoadjuvant chemo(radio)therapy on survival in 1,679 resected pancreatic carcinoma cases in Japan: Report of the national survey in the 34th annual meeting of Japanese Society of Pancreatic Surgery. J Hepatobiliary Pancreat Surg. 2009;16:485-92.
22. Artinyan A, Anaya DA, McKenzie S, Ellenhorn JD, Kim J. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer. 2011;117: 2044-9.
23. Laurence JM, Tran PD, Morarji K, Eslick GD, Lam VW, Sandroussi C. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg. 2011;15:2059-69.
24. Gillen S, Schuster T, Meyer zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267.
25. Ohigashi H, Ishikawa O, Eguchi H, Takahashi H, Gotoh K, Yamada T, et al. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent threedimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg. 2009;250:88-95.
26. Satoi S, Toyokawa H, Yanagimoto H, Yamamoto T, Kamata M, Ohe C, et al. Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer. J Gastrointest Surg. 2012;16:784-92.
27. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, et al. Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas. 2004;28:219-30.
28. Motoi F, Rikiyama T, Katayose Y, Egawa S, Unno M. Retrospective evaluation of the influence of postoperative tumor marker status on survival and patterns of recurrence after surgery for pancreatic cancer based on RECIST guidelines. Ann Surg Oncol. 2011;18:371-9.